There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Committee reports
Date published:
9 February 2022
Supplementary Legislative Consent Memorandums on the Health and Care Bill - Conclusions and recommendations
With respect to the relevant provisions of the Health and Care Bill, introduced in the House of Commons on 6 July 2021 relating to:
regulation of healthcare and associated professions;
food labelling for consumers;
international healthcare arrangements;
Medicine Information Systems;
virginity testing offences: Scotland;
Secretary of State’s power to transfe...
Committee reports
Date published:
3 February 2022
Supplementary Legislative Consent Memoranda: delegated powers relevant to Scotland in the Health and Care Bill - Outline of Supplementary LCMs
The first Supplementary LCM also indicates that amendments have been made to the power to make regulations to require NHS digital to collect information on the issue of medicines on a UK wide basis, which was in clause 85 of the Bill that was the subject of the original LCM and is now contained in clause 87.
Committee reports
Date published:
2 March 2021
Report on the impact of the COVID-19 pandemic on equalities and human rights - Disabilities and long-term health conditions
The key findings are:
Social care support has been stopped or reduced
People have new or increased caring responsibilities
Disabled people are struggling to get access to the food and medicine they need
People are being asked to sign Do Not Resuscitate (DNR) notices
People are concerned that they will lose their job
Social distancing and isolation are provi...
SPICe briefings
Date published:
2 September 2019
Preparing for a no-deal Brexit - Scottish Government approach to contingency planning
Cabinet is currently overseeing work on preparations for a possible ‘No Deal’ exit on 31 October, prioritising areas that will be heavily impacted such as the economy, transport, food and drink, medicines, agriculture and the rural economy.
Questions and Answers
Date answered:
11 January 2021
S5W-34085
The figures are in the following table. Domestic (£m) Non-domestic wholesale charges (£m) 2010-11 743.493 302.404 2011-12 745.563 294.706 2012-13 750.885 296.663 2013-14 778.809 293.633 2014-15 800.774 289.206 2015-16 820.677 291.502 2016-17 840.021 298.273 2017-18 860.866 320.476 2018-19 ...
Questions and Answers
Date answered:
10 January 2017
S5W-05714
However, since the Scottish Government took ownership, the income achieved, along with the operating loss, as reported in the Statement of Profit and Loss in the TS Prestwick Holdco Limited annual report and financial statements are: Year Turnover (income) £m Operating loss £m For the 17 month period ended 31 Mar...
Last updated:
2 April 2024
PB_2022_057
S6M-03233: Colette Stevenson: Access to Cannabis-based Products for Medicinal Use - That the Parliament welcomes the Home Office’s rescheduling of certain cannabis-based products for medicinal use (CBPMs) in 2018; notes the reported improvement in some children with treatment resistant epilepsy who take CBPMs, such as Cole Thomson, from East Kilbride, who it understands receives Bedrolite on private prescription; acknowledges the reported financial pressure that these prescriptions can place on families; further acknowledges the reported hesitancy of NHS consultants to prescribe unlicensed CBPMs due to the lack of robust evidence; notes the view that the rescheduling does not go far enough in assisting some patients, and the calls for a change in rules to allow GPs, who consider it appropriate, to prescribe unlicensed CBPMs where a non-NHS consultant has initiated that course of treatment; understands that the British Paediatric Neurology Association published its updated Guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy in October 2021, which, it considers, outlines concerns around the lack of randomised control trials demonstrating a product’s safety, quality and efficacy; acknowledges the Scottish Government’s reported commitment to collaborate with NHS England and the National Institute for Health Research to support research trials into medicinal cannabis in order to give NHS consultants the assurances that they need to consider prescribing CBPMs on the NHS; understands that, once a medicinal product has undergone clinical trials, it could be considered by the Medicines and Healthcare products Regulatory Agency for licensing and that this could lead to further consideration by organisations such as the National Institute for Health and Care Excellence, the Scottish Medicines Consortium and NHS Scotland; notes the calls for industry to run observational and clinical trials; believes that an increased evidence base offers the best opportunities for expansion of the range of CBPMs available from the NHS; welcomes the reported plans by Target Healthcare, which operates in East Kilbride, to produce CBPMs in Scotland, and notes the calls on the Scottish and UK governments to work together to find solutions on these issues.
Last updated:
2 April 2024
PB_2022_054
S6M-03233: Colette Stevenson: Access to Cannabis-based Products for Medicinal Use - That the Parliament welcomes the Home Office’s rescheduling of certain cannabis-based products for medicinal use (CBPMs) in 2018; notes the reported improvement in some children with treatment resistant epilepsy who take CBPMs, such as Cole Thomson, from East Kilbride, who it understands receives Bedrolite on private prescription; acknowledges the reported financial pressure that these prescriptions can place on families; further acknowledges the reported hesitancy of NHS consultants to prescribe unlicensed CBPMs due to the lack of robust evidence; notes the view that the rescheduling does not go far enough in assisting some patients, and the calls for a change in rules to allow GPs, who consider it appropriate, to prescribe unlicensed CBPMs where a non-NHS consultant has initiated that course of treatment; understands that the British Paediatric Neurology Association published its updated Guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy in October 2021, which, it considers, outlines concerns around the lack of randomised control trials demonstrating a product’s safety, quality and efficacy; acknowledges the Scottish Government’s reported commitment to collaborate with NHS England and the National Institute for Health Research to PB/S6/22/54 support research trials into medicinal cannabis in order to give NHS consultants the assurances that they need to consider prescribing CBPMs on the NHS; understands that, once a medicinal product has undergone clinical trials, it could be considered by the Medicines and Healthcare products Regulatory Agency for licensing and that this could lead to further consideration by organisations such as the National Institute for Health and Care Excellence, the Scottish Medicines Consortium and NHS Scotland; notes the calls for industry to run observational and clinical trials; believes that an increased evidence base offers the best opportunities for expansion of the range of CBPMs available from the NHS; welcomes the reported plans by Target Healthcare, which operates in East Kilbride, to produce CBPMs in Scotland, and notes the calls on the Scottish and UK governments to work together to find solutions on these issues.
Questions and Answers
Date answered:
24 February 2017
S5W-07512
Details of Boards’ revenue resource and capital allocations for 2017-18 are provided in the following tables: Revenue Resource: Territorial Boards 2017-18 uplift (£m) 2017-18 uplift % 2017-18 General allocation (£m) Other baseline transfers (£m) 2017-18 total % Ayrshir...
Last updated:
7 March 2023
BB20180910
Members are advised to lodge amendments in good time before the beginning of a Stage and as early as possible during the day. (G) = Government Bill; (M) = Member s Bill; (C) = Committee Bill; (P) = Private Bill; (H) = Hybrid ’ Bill.
